Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor
Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.
1. A therapeutic agent for glaucoma or ocular hypertension, wherein sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s) are administered in combination, and
wherein the Rho-associated coiled-coil containing protein kinase inhibitor(s) is at least one selected from the group consisting of ripasudil and a salt thereof, and
wherein sepetaprost and the Rho-associated coiled-coil containing protein kinase inhibitor(s) are administered simultaneously or concomitantly.
2. The therapeutic agent according to claim 1 , which is a combination drug comprising sepetaprost and the Rho-associated coiled-coil containing protein kinase inhibitor(s).
3. The therapeutic agent according to claim 1 , wherein sepetaprost and the Rho-associated coiled-coil containing protein kinase inhibitor(s) are administered at different times within 30 minutes.
4. A therapeutic agent for glaucoma or ocular hypertension comprising sepetaprost, which is used concomitantly with a Rho-associated coiled-coil containing protein kinase inhibitor(s),
wherein the Rho-associated coiled-coil containing protein kinase inhibitor(s) is at least one selected from the group consisting of ripasudil and a salt thereof.
5. The therapeutic agent according to claim 4 , which is administered at different time within 30 minutes from the Rho-associated coiled-coil containing protein kinase inhibitor(s).
6. The therapeutic agent according to claim 1 , wherein the Rho-associated coiled-coil containing protein kinase inhibitor(s) is ripasudil monohydrochloride dihydrate.
7. A therapeutic method for glaucoma or ocular hypertension comprising: administering a therapeutically effective amount of sepetaprost and a therapeutically effective amount of a Rho-associated coiled-coil containing protein kinase inhibitor(s) to a subject in need thereof,
wherein the Rho-associated coiled-coil containing protein kinase inhibitor(s) is at least one selected from the group consisting of ripasudil and a salt thereof, and
wherein sepetaprost and the Rho-associated coiled-coil containing protein kinase inhibitor(s) are administered simultaneously or concomitantly.
8. The therapeutic method for glaucoma or ocular hypertension according to claim 7 , wherein sepetaprost and the Rho-associated coiled-coil containing protein kinase inhibitor(s) are administered as a combination drug.
9. The therapeutic method for glaucoma or ocular hypertension according to claim 7 , wherein sepetaprost and the Rho-associated coiled-coil containing protein kinase inhibitor(s) are administered at different times within 30 minutes.
10. The therapeutic method for glaucoma or ocular hypertension according to claim 7 , wherein the Rho-associated coiled-coil containing protein kinase inhibitor(s) is ripasudil monohydrochloride dihydrate.
11. The therapeutic agent according to claim 4 , wherein the Rho-associated coiled-coil containing protein kinase inhibitor(s) is ripasudil monohydrochloride dihydrate.
12. The therapeutic agent according to claim 1 , wherein sepetaprost and the Rho-associated coiled-coil containing protein kinase inhibitor(s) are administered simultaneously.
13. The therapeutic agent according to claim 4 , which is administered simultaneously with the Rho-associated coiled-coil containing protein kinase inhibitor(s).
14. The therapeutic method for glaucoma or ocular hypertension according to claim 7 , wherein sepetaprost and the Rho-associated coiled-coil containing protein kinase inhibitor(s) are administered simultaneously.